Free Trial
→ Trump to unlock 15-figure fortune for America (May 3rd) ? (From Paradigm Press) (Ad) Buy MDGL Stock  Free MDGL Stock Alerts

Madrigal Pharmaceuticals (MDGL) Financials

Madrigal Pharmaceuticals logo
$322.32 +5.17 (+1.63%)
As of 04:00 PM Eastern
Compare
Annual Income Statements for Madrigal Pharmaceuticals

Annual Income Statements for Madrigal Pharmaceuticals

This table shows Madrigal Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Net Income / (Loss) Attributable to Common Shareholders		 -69 -26 -31 -33 -84 -202 -242 -295 -374 -466
Consolidated Net Income / (Loss)		 -69 -26 -31 -33 -84 -202 -242 -295 -374 -466
Net Income / (Loss) Continuing Operations		 -69 -26 -31 -33 -84 -202 -242 -295 -374 -466
Total Pre-Tax Income 		-69 -26 -31 -33 -84 -202 -242 -295 -374 -466
Total Operating Income		 -68 -25 -32 -41 -95 -207 -242 -294 -380 -498
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 174
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 180
Operating Revenue		 - - - 0.00 0.00 0.00 - 0.00 0.00 180
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 6.23
Operating Cost of Revenue		 - - - - - - - 0.00 0.00 6.23
Total Operating Expenses		 68 25 32 41 95 207 242 294 380 672
Selling, General & Admin Expense		 13 9.29 7.67 15 23 22 37 48 108 435
Research & Development Expense		 54 16 24 25 72 185 205 245 272 237
Total Other Income / (Expense), net		 -1.06 -1.17 0.91 7.87 11 4.43 0.64 -1.78 6.87 32
Interest Expense		 - 1.21 - - - 0.00 0.00 3.96 13 15
Interest & Investment Income		 -1.06 0.05 0.56 7.67 11 4.33 0.36 2.19 20 47
Basic Earnings per Share		 ($0.53) ($5.07) ($2.54) ($2.22) ($5.45) ($13.09) ($14.63) ($17.23) ($19.99) ($21.90)
Weighted Average Basic Shares Outstanding		 137.81M 5.20M 12.24M 14.80M 15.39M 15.45M 16.54M 17.14M 18.69M 21.27M
Diluted Earnings per Share		 ($0.53) ($5.07) ($2.54) ($2.22) ($5.45) ($13.09) ($14.63) ($17.23) ($19.99) ($21.90)
Weighted Average Diluted Shares Outstanding		 137.81M 5.20M 12.24M 14.80M 15.39M 15.45M 16.54M 17.14M 18.69M 21.27M
Weighted Average Basic & Diluted Shares Outstanding		 128.59M 5.20M 12.24M 14.80M 15.39M 15.45M 16.54M 18.14M 19.90M 22.08M

Quarterly Income Statements for Madrigal Pharmaceuticals

This table shows Madrigal Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Income / (Loss) Attributable to Common Shareholders		 -81 -86 -77 -86 -99 -112 -148 -152 -107 -59
Consolidated Net Income / (Loss)		 -81 -86 -77 -86 -99 -112 -148 -152 -107 -59
Net Income / (Loss) Continuing Operations		 -81 -86 -77 -86 -99 -112 -148 -152 -107 -59
Total Pre-Tax Income 		-81 -86 -77 -86 -99 -112 -148 -152 -107 -59
Total Operating Income		 -80 -85 -78 -86 -99 -117 -152 -163 -116 -67
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 15 62 97
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 15 62 103
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 6.23
Total Operating Expenses		 80 85 78 86 99 117 152 177 178 164
Selling, General & Admin Expense		 12 15 16 18 28 47 81 106 110 138
Research & Development Expense		 68 71 62 69 71 71 71 71 69 26
Total Other Income / (Expense), net		 -0.79 -0.61 1.44 0.65 -0.21 4.98 4.50 11 9.34 7.58
Interest Expense		 1.50 1.68 2.34 2.90 3.50 3.97 3.84 3.66 3.68 3.50
Interest & Investment Income		 0.72 1.08 3.78 3.55 3.30 8.95 8.33 14 13 11
Basic Earnings per Share		 ($4.75) ($4.98) ($4.23) ($4.69) ($5.34) ($5.73) ($7.38) ($7.10) ($4.92) ($2.50)
Weighted Average Basic Shares Outstanding		 17.10M 17.14M 18.19M 18.31M 18.48M 18.69M 20.00M 21.40M 21.75M 21.27M
Diluted Earnings per Share		 ($4.75) ($4.98) ($4.23) ($4.69) ($5.34) ($5.73) ($7.38) ($7.10) ($4.92) ($2.50)
Weighted Average Diluted Shares Outstanding		 17.10M 17.14M 18.19M 18.31M 18.48M 18.69M 20.00M 21.40M 21.75M 21.27M
Weighted Average Basic & Diluted Shares Outstanding		 17.10M 18.14M 18.29M 18.47M 19.74M 19.90M 21.31M 21.71M 21.81M 22.08M

Annual Cash Flow Statements for Madrigal Pharmaceuticals

This table details how cash moves in and out of Madrigal Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Net Change in Cash & Equivalents		 0.16 19 129 -91 -11 7.31 -18 295 -232 5.10
Net Cash From Operating Activities		 -3.14 -18 -22 -26 -42 -158 -184 -225 -324 -456
Net Cash From Continuing Operating Activities		 -3.14 -18 -22 -26 -42 -158 -184 -225 -324 -456
Net Income / (Loss) Continuing Operations		 -6.84 -26 -31 -33 -84 -202 -242 -295 -374 -466
Consolidated Net Income / (Loss)		 -6.84 -26 -31 -33 -84 -202 -242 -295 -374 -466
Depreciation Expense		 - 0.00 0.08 0.10 0.11 0.47 0.41 0.47 0.53 1.10
Amortization Expense		 - - - - - 0.00 0.00 0.80 2.41 1.69
Non-Cash Adjustments To Reconcile Net Income		 3.61 9.89 3.25 9.82 26 23 28 32 44 56
Changes in Operating Assets and Liabilities, net		 0.09 -1.11 5.51 -2.61 16 22 30 38 2.17 -48
Net Cash From Investing Activities		 0.00 22 -22 -380 31 160 -5.06 207 -503 -274
Net Cash From Continuing Investing Activities		 0.00 22 -22 -380 31 160 -5.06 207 -503 -274
Purchase of Property, Plant & Equipment		 - -0.00 -0.13 -0.02 -0.17 -0.33 -0.21 -0.22 -1.48 -1.46
Acquisitions		 - - - - - - - 0.00 0.00 -5.00
Purchase of Investments		 - -11 -70 -614 -619 -329 -394 -143 -834 -1,131
Sale and/or Maturity of Investments		 - 26 48 234 650 489 389 350 333 863
Net Cash From Financing Activities		 3.30 14 174 314 0.24 5.09 171 313 595 735
Net Cash From Continuing Financing Activities		 3.30 14 174 314 0.24 5.09 171 313 595 735
Repayment of Debt		 - - - - - 0.00 0.00 -0.89 -0.36 0.00
Issuance of Debt		 2.80 8.50 - - - 0.00 0.00 50 65 0.00
Issuance of Common Equity		 0.00 0.00 - - - 4.42 171 264 530 735

Quarterly Cash Flow Statements for Madrigal Pharmaceuticals

This table details how cash moves in and out of Madrigal Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Change in Cash & Equivalents		 6.07 272 -218 -36 -15 38 523 -123 -262 -133
Net Cash From Operating Activities		 -59 -59 -84 -75 -85 -80 -149 -135 -67 -104
Net Cash From Continuing Operating Activities		 -59 -59 -84 -75 -85 -80 -149 -135 -67 -105
Net Income / (Loss) Continuing Operations		 -81 -86 -77 -86 -99 -112 -148 -152 -107 -59
Consolidated Net Income / (Loss)		 -81 -86 -77 -86 -99 -112 -148 -152 -107 -59
Depreciation Expense		 0.12 0.13 0.12 0.13 0.14 0.14 0.17 0.27 0.30 0.36
Amortization Expense		 0.31 0.31 0.43 0.55 0.67 0.75 0.66 0.47 0.48 0.08
Non-Cash Adjustments To Reconcile Net Income		 7.80 8.50 9.08 9.58 13 13 19 15 18 4.34
Changes in Operating Assets and Liabilities, net		 14 18 -17 0.23 -0.08 19 -21 1.76 21 -50
Net Cash From Investing Activities		 65 66 -187 -3.73 50 -362 98 -122 -202 -48
Net Cash From Continuing Investing Activities		 65 66 -187 -3.73 50 -362 98 -122 -202 -48
Purchase of Property, Plant & Equipment		 -0.03 -0.03 -0.04 -0.07 -0.34 -1.04 -0.36 -0.13 -0.78 -0.20
Purchase of Investments		 -14 -13 -199 -92 -69 -475 -84 -281 -416 -350
Sale and/or Maturity of Investments		 79 79 12 88 119 114 183 164 214 302
Net Cash From Financing Activities		 - 264 53 43 20 480 574 134 7.46 20
Net Cash From Continuing Financing Activities		 - 264 53 43 20 480 574 134 7.46 20
Issuance of Common Equity		 - - 18 28 4.66 480 574 134 7.46 20

Annual Balance Sheets for Madrigal Pharmaceuticals

This table presents Madrigal Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Total Assets		 0.36 41 192 485 442 287 273 363 641 1,042
Total Current Assets		 0.36 41 192 485 440 285 272 361 637 1,033
Cash & Equivalents		 0.31 19 149 57 47 54 36 332 100 100
Restricted Cash		 - - - - - - - - 0.00 5.00
Short-Term Investments		 - 21 43 426 392 230 234 27 534 826
Accounts Receivable		 0.01 - - - - - - - 0.00 54
Inventories, net		 - - - - - - - - 0.00 34
Prepaid Expenses		 0.05 0.71 0.49 1.48 1.15 1.01 1.34 2.60 3.15 14
Plant, Property, & Equipment, net		 0.00 0.00 0.30 0.23 1.18 1.05 0.85 0.60 1.55 2.19
Total Noncurrent Assets		 0.00 0.00 0.00 0.00 0.68 0.79 0.80 0.60 1.71 7.13
Intangible Assets		 - - - - - - - - 0.00 4.73
Other Noncurrent Operating Assets		 - - - - 0.68 0.79 0.80 0.60 1.71 2.40
Total Liabilities & Shareholders' Equity		 0.36 41 192 485 442 287 273 363 641 1,042
Total Liabilities		 49 4.80 10 8.44 25 47 77 165 235 288
Total Current Liabilities		 49 4.80 10 8.44 25 47 77 116 119 169
Accounts Payable		 0.10 0.76 1.93 2.49 1.18 1.02 21 24 28 44
Accrued Expenses		 0.07 4.04 8.13 5.96 24 45 55 91 90 125
Other Current Liabilities		 - - - - 0.32 0.32 0.41 0.60 0.53 0.98
Total Noncurrent Liabilities		 0.00 0.00 0.00 0.00 0.36 0.47 0.39 49 117 119
Long-Term Debt		 - - - - - - 0.00 49 115 118
Other Noncurrent Operating Liabilities		 - - - - 0.36 0.47 0.39 0.00 1.19 1.02
Total Equity & Noncontrolling Interests		 -49 36 182 477 417 240 196 197 405 754
Total Preferred & Common Equity		 -49 36 182 477 417 240 196 197 405 754
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -49 36 182 477 417 240 196 197 405 754
Common Stock		 0.01 112 289 617 640 665 863 1,160 1,741 2,556
Retained Earnings		 -49 -75 -106 -139 -223 -425 -667 -963 -1,336 -1,802
Accumulated Other Comprehensive Income / (Loss)		 - 0.03 -0.03 -0.32 0.22 0.05 -0.08 -0.03 0.47 0.47

Quarterly Balance Sheets for Madrigal Pharmaceuticals

This table presents Madrigal Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Total Assets		 159 332 302 238 1,082 1,100 1,073
Total Current Assets		 157 331 302 235 1,074 1,092 1,064
Cash & Equivalents		 59 113 77 62 623 495 233
Restricted Cash		 - - - - - 5.00 5.00
Short-Term Investments		 94 216 221 170 437 563 766
Accounts Receivable		 - - - - - 6.90 30
Inventories, net		 - - - - 0.85 7.07 8.72
Prepaid Expenses		 3.92 1.81 3.18 3.12 14 15 21
Plant, Property, & Equipment, net		 0.70 0.51 0.46 0.66 1.74 1.70 2.27
Total Noncurrent Assets		 0.83 0.65 0.41 1.84 6.59 6.37 7.33
Intangible Assets		 - - - - 5.00 4.91 4.82
Other Noncurrent Operating Assets		 0.83 0.65 0.41 1.84 1.59 1.46 2.51
Total Liabilities & Shareholders' Equity		 159 332 302 238 1,082 1,100 1,073
Total Liabilities		 148 182 199 216 232 243 296
Total Current Liabilities		 99 98 100 100 114 125 178
Accounts Payable		 19 12 18 17 22 8.99 46
Accrued Expenses		 80 86 82 83 92 116 131
Other Current Liabilities		 0.76 0.65 0.41 0.51 0.54 0.56 0.88
Total Noncurrent Liabilities		 49 84 99 116 117 118 118
Long-Term Debt		 49 84 99 115 116 117 117
Other Noncurrent Operating Liabilities		 0.07 - - 1.32 1.05 0.90 1.18
Total Equity & Noncontrolling Interests		 11 150 104 22 851 857 777
Total Preferred & Common Equity		 11 150 104 22 851 857 777
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 11 150 104 22 851 857 777
Common Stock		 888 1,190 1,229 1,246 2,335 2,493 2,519
Retained Earnings		 -877 -1,040 -1,125 -1,224 -1,484 -1,636 -1,743
Accumulated Other Comprehensive Income / (Loss)		 -0.24 -0.09 -0.09 -0.04 -0.17 -0.37 1.27

Annual Metrics and Ratios for Madrigal Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Madrigal Pharmaceuticals' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 18.81% 0.00% -25.42% -27.66% -134.88% -117.27% -17.32% -20.89% -29.16% -31.13%
EBIT Growth		 19.46% 0.00% -25.73% -27.66% -134.60% -117.51% -17.25% -21.21% -29.61% -30.85%
NOPAT Growth		 19.46% 0.00% -27.11% -26.89% -133.45% -117.61% -17.33% -21.07% -29.61% -30.85%
Net Income Growth		 20.30% 0.00% -18.06% -5.32% -155.85% -140.92% -19.58% -22.12% -26.50% -24.69%
EPS Growth		 39.08% 0.00% 49.90% 12.60% -145.50% -140.18% -11.76% -17.77% -16.02% -9.55%
Operating Cash Flow Growth		 96.02% -460.44% -26.74% -14.29% -63.19% -278.53% -16.73% -22.26% -44.19% -40.51%
Free Cash Flow Firm Growth		 -10.57% 0.00% 0.00% -79.62% -63.60% -142.38% -13.58% -20.02% -58.15% -51.83%
Invested Capital Growth		 96.65% 0.00% -126.60% 27.34% -233.83% -96.53% -68.04% -50.99% -1.09% 47.67%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 134.51%
EBITDA Q/Q Growth		 -11.55% 0.00% 0.00% 0.00% -19.53% -16.65% -2.14% -7.49% -9.08% 9.13%
EBIT Q/Q Growth		 -11.55% 0.00% 0.00% 0.00% -19.50% -16.66% -2.13% -7.59% -9.14% 9.16%
NOPAT Q/Q Growth		 -11.55% 0.00% 0.00% 0.00% -19.50% -16.72% -2.13% -7.59% -9.14% 9.16%
Net Income Q/Q Growth		 -9.60% 0.00% 0.00% 0.00% -24.03% -18.37% -2.30% -7.79% -7.57% 10.18%
EPS Q/Q Growth		 93.87% 0.00% 0.00% 0.00% -23.58% -18.25% 0.14% -7.35% -3.90% 12.85%
Operating Cash Flow Q/Q Growth		 85.22% -31.17% -3.07% -1.27% -16.90% -37.13% 3.61% -4.88% -7.07% -5.70%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -35.17% 5.74% -3.65% -9.47% -8.90%
Invested Capital Q/Q Growth		 97.01% 0.00% 0.00% 0.00% -69.52% 4.44% -15.52% -19.84% -18.81% 45.79%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 96.54%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -274.85%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -276.39%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -276.39%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -258.64%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 101.57% 104.62% 98.24% 81.05% 88.39% 97.90% 99.85% 100.61% 98.20% 93.58%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -846.61% 422.09% -28.49% -9.95% -18.79% -61.61% -110.92% -150.12% -123.98% -80.35%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -59.17%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -55.37%
Return on Common Equity (ROCE)		 -846.61% 422.09% -28.49% -9.95% -18.79% -61.61% -110.92% -150.12% -123.98% -80.35%
Return on Equity Simple (ROE_SIMPLE)		 140.39% -72.47% -17.09% -6.88% -20.15% -84.28% -123.32% -149.63% -92.18% -61.76%
Net Operating Profit after Tax (NOPAT)		 -47 -18 -22 -28 -66 -145 -170 -205 -266 -349
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -193.48%
Net Nonoperating Expense Percent (NNEP)		 -120.26% -21.56% -7.51% -1.28% -3.79% -15.92% -26.01% -30.99% -25.91% -17.62%
Return On Investment Capital (ROIC_SIMPLE)		 14,873.68% - - - - - - -83.31% -51.14% -39.97%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 3.46%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 241.52%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 131.41%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 372.93%
Earnings before Interest and Taxes (EBIT)		 -68 -25 -32 -40 -95 -207 -242 -294 -380 -498
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -68 -25 -32 -40 -95 -206 -242 -292 -378 -495
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 4.73 6.29 3.64 3.37 7.17 7.39 25.15 11.27 8.92
Price to Tangible Book Value (P/TBV)		 0.00 4.73 6.29 3.64 3.37 7.17 7.39 25.15 11.27 8.98
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 37.36
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 32.84
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 -0.99 0.00 0.00 0.00 0.00 0.00 0.00 0.25 0.28 0.16
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.25 0.28 0.16
Financial Leverage		 -2.19 -1.11 -1.06 -1.02 -1.03 -1.10 -1.27 -1.47 -1.37 -1.15
Leverage Ratio		 6.23 -3.33 1.07 1.03 1.04 1.11 1.28 1.62 1.66 1.45
Compound Leverage Factor		 6.33 -3.48 1.05 0.83 0.92 1.09 1.28 1.63 1.63 1.36
Debt to Total Capital		 -15,272.23% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 19.98% 22.17% 13.48%
Short-Term Debt to Total Capital		 -15,272.23% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 19.98% 22.17% 13.48%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 15,372.23% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 80.02% 77.83% 86.52%
Debt to EBITDA		 -0.72 0.00 0.00 0.00 0.00 0.00 0.00 -0.17 -0.31 -0.24
Net Debt to EBITDA		 -0.71 0.00 0.00 0.00 0.00 0.00 0.00 1.06 1.37 1.64
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.17 -0.31 -0.24
Debt to NOPAT		 -1.03 0.00 0.00 0.00 0.00 0.00 0.00 -0.24 -0.43 -0.34
Net Debt to NOPAT		 -1.02 0.00 0.00 0.00 0.00 0.00 0.00 1.51 1.95 2.33
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.24 -0.43 -0.34
Altman Z-Score		 -962.87 18.03 68.27 123.79 32.80 18.49 5.77 12.46 7.74 11.20
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 0.01 8.58 19.10 57.46 17.52 6.13 3.54 3.12 5.38 6.10
Quick Ratio		 0.01 8.44 19.05 57.29 17.47 6.10 3.52 3.10 5.35 5.79
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -65 0.00 -17 -31 -51 -123 -140 -168 -265 -403
Operating Cash Flow to CapEx		 0.00% 0.00% -17,853.60% -115,940.91% -24,200.00% -47,173.95% -87,998.56% -103,620.74% -21,922.24% -31,160.88%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -42.29 -20.86 -27.44
Operating Cash Flow to Interest Expense		 0.00 -14.52 0.00 0.00 0.00 0.00 0.00 -56.72 -25.51 -31.05
Operating Cash Flow Less CapEx to Interest Expense		 0.00 -13.94 0.00 0.00 0.00 0.00 0.00 -56.78 -25.62 -31.15
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.21
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 96.25
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.17
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2,097.59
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -2,097.59
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 -0.62 -4.09 -9.27 -6.73 -22 -44 -74 -112 -113 -59
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -2.09
Increase / (Decrease) in Invested Capital		 18 0.00 -5.18 2.53 -16 -22 -30 -38 -1.22 54
Enterprise Value (EV)		 97 132 955 1,251 967 1,435 1,178 4,655 4,049 5,916
Market Capitalization		 49 172 1,147 1,735 1,406 1,719 1,449 4,964 4,568 6,730
Book Value per Share		 ($0.36) $3.15 $14.59 $30.99 $27.00 $15.52 $11.47 $11.54 $20.53 $34.59
Tangible Book Value per Share		 ($0.36) $3.15 $14.59 $30.99 $27.00 $15.52 $11.47 $11.54 $20.53 $34.37
Total Capital		 -0.32 36 182 477 417 240 196 247 521 872
Total Debt		 49 0.00 0.00 0.00 0.00 0.00 0.00 49 115 118
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 49 115 118
Net Debt		 48 -41 -192 -484 -439 -284 -270 -309 -519 -814
Capital Expenditures (CapEx)		 0.00 -0.70 0.13 0.02 0.17 0.33 0.21 0.22 1.48 1.46
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.62 -4.09 -9.57 -6.96 -24 -46 -76 -113 -115 -68
Debt-free Net Working Capital (DFNWC)		 -0.32 36 182 477 415 239 195 245 519 864
Net Working Capital (NWC)		 -49 36 182 477 415 239 195 245 519 864
Net Nonoperating Expense (NNE)		 21 8.73 8.71 4.33 17 58 72 90 107 117
Net Nonoperating Obligations (NNO)		 48 -41 -192 -484 -439 -284 -270 -309 -519 -814
Total Depreciation and Amortization (D&A)		 0.00 0.00 0.08 0.10 0.11 0.47 0.41 1.26 2.94 2.79
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -37.53%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 479.45%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 479.45%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($18.55) ($5.07) ($2.54) ($2.22) ($5.45) $0.00 $0.00 $0.00 ($19.99) ($21.90)
Adjusted Weighted Average Basic Shares Outstanding		 3.94M 12.17M 14.23M 15.42M 15.43M 0.00 0.00 0.00 18.69M 21.27M
Adjusted Diluted Earnings per Share		 ($18.55) ($5.07) ($2.54) ($2.22) ($5.45) $0.00 $0.00 $0.00 ($19.99) ($21.90)
Adjusted Weighted Average Diluted Shares Outstanding		 3.94M 12.17M 14.23M 15.42M 15.43M 0.00 0.00 0.00 18.69M 21.27M
Adjusted Basic & Diluted Earnings per Share		 ($18.55) ($5.07) ($2.54) ($2.22) ($5.45) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 3.67M 5.20M 12.24M 14.80M 15.39M 0.00 0.00 0.00 19.90M 22.08M
Normalized Net Operating Profit after Tax (NOPAT)		 -47 -18 -22 -28 -66 -145 -170 -205 -266 -349
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -193.48%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -258.64%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 -20.79 0.00 0.00 0.00 0.00 0.00 -74.06 -29.93 -33.94
NOPAT to Interest Expense		 0.00 -14.56 0.00 0.00 0.00 0.00 0.00 -51.84 -20.95 -23.76
EBIT Less CapEx to Interest Expense		 0.00 -20.22 0.00 0.00 0.00 0.00 0.00 -74.11 -30.05 -34.04
NOPAT Less CapEx to Interest Expense		 0.00 -13.98 0.00 0.00 0.00 0.00 0.00 -51.90 -21.07 -23.85
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics and Ratios for Madrigal Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Madrigal Pharmaceuticals' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -26.82% -31.58% -35.31% -22.55% -22.19% -37.02% -94.41% -88.64% -18.22% 42.77%
EBIT Growth		 -27.31% -32.04% -36.03% -23.02% -22.54% -37.37% -94.08% -88.01% -18.03% 42.82%
NOPAT Growth		 -27.31% -32.04% -36.03% -23.02% -22.54% -37.37% -94.08% -88.01% -18.03% 42.82%
Net Income Growth		 -28.68% -33.08% -33.69% -21.31% -21.61% -30.60% -91.87% -77.12% -8.33% 47.04%
EPS Growth		 -25.33% -31.05% -25.89% -13.29% -12.42% -15.06% -74.47% -51.39% 7.87% 56.37%
Operating Cash Flow Growth		 -29.66% -21.78% -68.43% -31.29% -43.76% -36.60% -77.43% -79.19% 21.12% -30.72%
Free Cash Flow Firm Growth		 -3.17% -44.14% -163.59% -94.58% -148.54% -269.76% -225.63% -171.03% -0.39% -24.90%
Invested Capital Growth		 -45.56% -50.99% -28.52% -20.24% -1.96% -1.09% 3.36% 6.90% -14.69% 47.67%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 324.75% 66.18%
EBITDA Q/Q Growth		 -14.28% -6.11% 8.35% -10.27% -13.94% -18.99% -30.04% -7.00% 28.60% 42.39%
EBIT Q/Q Growth		 -14.43% -6.08% 8.16% -10.36% -13.98% -18.92% -29.75% -6.91% 28.44% 42.39%
NOPAT Q/Q Growth		 -14.43% -6.08% 8.16% -10.36% -13.98% -18.92% -29.75% -6.91% 28.44% 42.39%
Net Income Q/Q Growth		 -14.80% -5.80% 10.49% -11.58% -15.08% -13.63% -31.51% -3.00% 29.62% 44.45%
EPS Q/Q Growth		 -14.73% -4.84% 15.06% -10.87% -13.86% -7.30% -28.80% 3.79% 30.70% 49.19%
Operating Cash Flow Q/Q Growth		 -2.98% 0.94% -43.67% 10.42% -12.76% 5.87% -86.60% 9.53% 50.36% -55.99%
Free Cash Flow Firm Q/Q Growth		 -18.35% 19.10% -54.07% -31.91% -51.17% -20.35% -35.68% -9.80% 44.00% -49.72%
Invested Capital Q/Q Growth		 -17.57% -19.84% 14.92% -0.30% 0.30% -18.81% 18.66% 3.37% -22.81% 45.79%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 100.00% 100.00% 93.97%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,105.33% -185.81% -64.41%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,110.38% -187.06% -64.84%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,110.38% -187.06% -64.84%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,038.20% -172.04% -57.51%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.98% 100.71% 98.16% 99.25% 100.21% 95.75% 97.04% 93.50% 91.97% 88.68%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -223.17% -150.12% -212.74% -352.65% -2,110.28% -123.98% -88.78% -106.27% -129.76% -80.35%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -23.18% -21.92% -13.88%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -21.68% -20.16% -12.31%
Return on Common Equity (ROCE)		 -223.17% -150.12% -212.74% -352.65% -2,110.28% -123.98% -88.78% -106.27% -129.76% -80.35%
Return on Equity Simple (ROE_SIMPLE)		 -2,567.89% 0.00% -209.63% -318.63% -1,561.15% 0.00% -52.22% -59.55% -66.74% 0.00%
Net Operating Profit after Tax (NOPAT)		 -56 -60 -55 -61 -69 -82 -106 -114 -81 -47
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -777.26% -130.94% -45.39%
Net Nonoperating Expense Percent (NNEP)		 -12.35% -9.04% -9.48% -13.96% -26.84% -7.29% -6.92% -6.67% -5.09% -1.88%
Return On Investment Capital (ROIC_SIMPLE)		 - -24.21% - - - -15.75% - - - -5.38%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 6.03%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 724.72% 176.50% 133.99%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 485.66% 110.56% 24.82%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1,210.38% 287.06% 158.81%
Earnings before Interest and Taxes (EBIT)		 -80 -85 -78 -86 -99 -117 -152 -163 -116 -67
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -80 -85 -78 -86 -98 -116 -151 -162 -116 -67
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 104.18 25.15 29.27 40.82 121.24 11.27 6.20 6.97 5.93 8.92
Price to Tangible Book Value (P/TBV)		 104.18 25.15 29.27 40.82 121.24 11.27 6.23 7.01 5.97 8.98
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 407.89 59.99 37.36
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 343.25 48.45 32.84
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 4.59 0.25 0.56 0.96 5.16 0.28 0.14 0.14 0.15 0.16
Long-Term Debt to Equity		 4.59 0.25 0.56 0.96 5.16 0.28 0.14 0.14 0.15 0.16
Financial Leverage		 -1.64 -1.47 -1.57 -1.94 -6.74 -1.37 -1.19 -1.19 -1.26 -1.15
Leverage Ratio		 1.89 1.62 1.88 2.77 12.05 1.66 1.41 1.46 1.64 1.45
Compound Leverage Factor		 1.91 1.63 1.84 2.75 12.07 1.59 1.37 1.36 1.51 1.29
Debt to Total Capital		 82.11% 19.98% 35.87% 48.95% 83.76% 22.17% 12.01% 11.98% 13.09% 13.48%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 82.11% 19.98% 35.87% 48.95% 83.76% 22.17% 12.01% 11.98% 13.09% 13.48%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 17.89% 80.02% 64.13% 51.05% 16.24% 77.83% 87.99% 88.02% 86.91% 86.52%
Debt to EBITDA		 -0.18 -0.17 -0.27 -0.30 -0.33 -0.31 -0.26 -0.22 -0.21 -0.24
Net Debt to EBITDA		 0.38 1.06 0.79 0.61 0.34 1.37 2.09 1.80 1.63 1.64
Long-Term Debt to EBITDA		 -0.18 -0.17 -0.27 -0.30 -0.33 -0.31 -0.26 -0.22 -0.21 -0.24
Debt to NOPAT		 -0.26 -0.24 -0.38 -0.43 -0.47 -0.43 -0.37 -0.31 -0.31 -0.34
Net Debt to NOPAT		 0.55 1.51 1.12 0.86 0.48 1.95 2.97 2.55 2.31 2.33
Long-Term Debt to NOPAT		 -0.26 -0.24 -0.38 -0.43 -0.47 -0.43 -0.37 -0.31 -0.31 -0.34
Altman Z-Score		 -4.46 14.35 10.15 7.39 -0.38 9.10 12.34 13.26 7.77 12.56
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 1.59 3.12 3.37 3.02 2.36 5.38 9.39 8.72 5.98 6.10
Quick Ratio		 1.55 3.10 3.35 2.99 2.33 5.35 9.26 8.51 5.79 5.79
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -27 -22 -34 -44 -67 -81 -110 -120 -67 -101
Operating Cash Flow to CapEx		 -178,996.97% -201,775.86% -240,191.43% -109,144.93% -25,050.15% -7,715.54% -41,780.67% -103,011.45% -8,598.72% -53,582.56%
Free Cash Flow to Firm to Interest Expense		 -17.98 -12.99 -14.41 -15.31 -19.16 -20.35 -28.57 -32.92 -18.32 -28.85
Operating Cash Flow to Interest Expense		 -39.33 -34.79 -35.99 -25.96 -24.24 -20.13 -38.86 -36.91 -18.21 -29.87
Operating Cash Flow Less CapEx to Interest Expense		 -39.35 -34.81 -36.00 -25.98 -24.33 -20.39 -38.96 -36.95 -18.42 -29.93
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.12 0.21
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 13.62 52.49 96.25
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.17
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2,097.59
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -2,097.59
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 -94 -112 -95 -96 -95 -113 -92 -89 -109 -59
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.16 -0.75 -2.09
Increase / (Decrease) in Invested Capital		 -29 -38 -21 -16 -1.84 -1.22 3.21 6.60 -14 54
Enterprise Value (EV)		 1,007 4,655 4,149 4,026 2,580 4,049 4,329 5,024 3,721 5,916
Market Capitalization		 1,112 4,964 4,394 4,225 2,698 4,568 5,272 5,971 4,608 6,730
Book Value per Share		 $0.62 $11.54 $8.28 $5.66 $1.20 $20.53 $42.53 $40.22 $35.79 $34.59
Tangible Book Value per Share		 $0.62 $11.54 $8.28 $5.66 $1.20 $20.53 $42.28 $39.99 $35.57 $34.37
Total Capital		 60 247 234 203 137 521 967 974 894 872
Total Debt		 49 49 84 99 115 115 116 117 117 118
Total Long-Term Debt		 49 49 84 99 115 115 116 117 117 118
Net Debt		 -104 -309 -246 -199 -118 -519 -943 -946 -887 -814
Capital Expenditures (CapEx)		 0.03 0.03 0.04 0.07 0.34 1.04 0.36 0.13 0.78 0.20
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -95 -113 -97 -97 -97 -115 -99 -96 -118 -68
Debt-free Net Working Capital (DFNWC)		 58 245 233 202 136 519 960 967 886 864
Net Working Capital (NWC)		 58 245 233 202 136 519 960 967 886 864
Net Nonoperating Expense (NNE)		 25 26 22 25 30 30 41 38 26 13
Net Nonoperating Obligations (NNO)		 -104 -309 -246 -199 -118 -519 -943 -946 -887 -814
Total Depreciation and Amortization (D&A)		 0.43 0.44 0.56 0.68 0.81 0.90 0.82 0.74 0.78 0.45
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -657.38% -153.37% -37.53%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 6,603.13% 1,153.22% 479.45%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 6,603.13% 1,153.22% 479.45%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($4.75) ($4.98) ($4.23) ($4.69) ($5.34) ($5.73) ($7.38) ($7.10) ($4.92) ($2.50)
Adjusted Weighted Average Basic Shares Outstanding		 17.10M 17.14M 18.19M 18.31M 18.48M 18.69M 20.00M 21.40M 21.75M 21.27M
Adjusted Diluted Earnings per Share		 ($4.75) ($4.98) ($4.23) ($4.69) ($5.34) ($5.73) ($7.38) ($7.10) ($4.92) ($2.50)
Adjusted Weighted Average Diluted Shares Outstanding		 17.10M 17.14M 18.19M 18.31M 18.48M 18.69M 20.00M 21.40M 21.75M 21.27M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 17.10M 18.14M 18.29M 18.47M 19.74M 19.90M 21.31M 21.71M 21.81M 22.08M
Normalized Net Operating Profit after Tax (NOPAT)		 -56 -60 -55 -61 -69 -82 -106 -114 -81 -47
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -777.26% -130.94% -45.39%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,038.20% -172.04% -57.51%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 -53.54 -50.71 -33.53 -29.80 -28.12 -29.51 -39.61 -44.46 -31.61 -19.15
NOPAT to Interest Expense		 -37.48 -35.50 -23.47 -20.86 -19.68 -20.66 -27.73 -31.12 -22.13 -13.41
EBIT Less CapEx to Interest Expense		 -53.56 -50.73 -33.55 -29.82 -28.22 -29.77 -39.71 -44.49 -31.82 -19.21
NOPAT Less CapEx to Interest Expense		 -37.50 -35.52 -23.49 -20.88 -19.78 -20.92 -27.82 -31.16 -22.34 -13.46
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Madrigal Pharmaceuticals' Financials

When does Madrigal Pharmaceuticals's financial year end?

According to the most recent income statement we have on file, Madrigal Pharmaceuticals' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Madrigal Pharmaceuticals' net income changed over the last 9 years?

Madrigal Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$465.89 million in 2024, rising from -$68.67 million in 2015. The previous period was -$373.63 million in 2023.

What is Madrigal Pharmaceuticals's operating income?
Madrigal Pharmaceuticals's total operating income in 2024 was -$497.88 million, based on the following breakdown:
  • Total Gross Profit: $173.90 million
  • Total Operating Expenses: $671.78 million
How has Madrigal Pharmaceuticals revenue changed over the last 9 years?

Over the last 9 years, Madrigal Pharmaceuticals' total revenue changed from $0.00 in 2015 to $180.13 million in 2024, a change of 18,013,300,000.0%.

How much debt does Madrigal Pharmaceuticals have?

Madrigal Pharmaceuticals' total liabilities were at $287.86 million at the end of 2024, a 22.4% increase from 2023, and a 484.2% increase since 2015.

How much cash does Madrigal Pharmaceuticals have?

In the past 9 years, Madrigal Pharmaceuticals' cash and equivalents has ranged from $306.25 thousand in 2015 to $331.55 million in 2022, and is currently $100.02 million as of their latest financial filing in 2024.

How has Madrigal Pharmaceuticals' book value per share changed over the last 9 years?

Over the last 9 years, Madrigal Pharmaceuticals' book value per share changed from -0.36 in 2015 to 34.59 in 2024, a change of -9,843.2%.

Remove Ads

Related Companies

This page (NASDAQ:MDGL) was last updated on 4/14/2025 by MarketBeat.com Staff
From Our Partners
Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...
Altimetry | Sponsored
Claim Your FREE Protection Guide
In the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...
American Alternative | Sponsored
America’s Retirement Accounts Are at Risk—Here’s Why
When Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...
Premier Gold Co | Sponsored
Tariffs. Volatility. Fear. Here’s the Plan.
Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...
Investors Alley | Sponsored
Catastrophic
The losses are catastrophic... $760 billion wiped off the Magnificent 7, in a single day.
InvestorPlace | Sponsored
Trump’s betrayal exposed
Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...
Porter & Company | Sponsored
Trump 2028 could be a “bonanza” for investors
As you may have heard, Donald Trump is planning to run for a THIRD term in 2028. Recently he told NBC news ...
Paradigm Press | Sponsored
If Gold Is ‘Stalling,’ Why Are Banks Hoarding Billions In Secret?
Prosperity was something every American family could build, protect, and pass down. Because that's what legacy...
Colonial Metals | Sponsored